Article Text

Download PDFPDF
High prevalence of serrated polyposis syndrome in FIT-based colorectal cancer screening programmes
  1. Leticia Moreira1,
  2. Maria Pellisé1,
  3. Sabela Carballal1,
  4. Xavier Bessa2,
  5. Teresa Ocaña1,
  6. Anna Serradesanferm1,
  7. Jaume Grau1,
  8. Francesc Macià2,
  9. Montserrat Andreu2,
  10. Antoni Castells1,
  11. Francesc Balaguer1,
  12. on behalf of the PROCOLON research group
  1. 1Department of Gastroenterology, Hospital Clínic, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), IDIBAPS, University of Barcelona, Barcelona, Catalonia, Spain
  2. 2Department of Gastroenterology, Hospital del Mar, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, Spain
  1. Correspondence to Dr Francesc Balaguer, Department of Gastroenterology, Hospital Clínic, Villarroel 170, Barcelona, Catalonia 08036, Spain; fprunes{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Serrated polyposis syndrome (SPS) is a recently recognised high risk condition for colorectal cancer (CRC) characterised by the presence of large and/or multiple serrated polyps in the colon.1 ,2 The prevalence of SPS has been previously estimated out of CRC endoscopy-based screening programmes on average risk individuals; in this setting, the prevalence ranged from 0.033% (1/3000 sigmoidoscopies)3 to 0.055% (1/1818 colonoscopies).4 However, Biswas et al 5 recently published a higher prevalence based on a guaiac faecal  occult blood testing (gFOBT) CRC screening programme in the UK (NHS Bowel Cancer Screening Programme). In this programme, between April 2010 and January 2012, 5/755 (0.66%) patients attended for index screening colonoscopy after a positive gFOBT met the WHO criteria for SPS, which represented a 20-fold increase …

View Full Text


  • Contributors FB, AC, MA: study concept and design; FB, LM, MP, SC, XB, TO, AS, JG, FM: acquisition of data; FB, LM: analysis and interpretation of data; FB, LM: drafting of the manuscript; MA, AC: critical revision of the manuscript for important intellectual content; FB, LM: statistical analysis.

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval IRB of each participating institution.

  • Provenance and peer review Not commissioned; internally peer reviewed.